Toward a pharmacophore for kinase frequent hitters

被引：49

作者：

Aronov, AM ^{[1
]}

Murcko, MA ^{[1
]}

机构：

[1] Vertex Pharmaceut Inc, Cambridge, MA 02139 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 23期

关键词：

D O I：

10.1021/jm049793g

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Small molecule protein kinase inhibitors are widely employed as biological reagents and as leads in the design of drugs for a variety of diseases. One of the hardest challenges in kinase inhibitor design is achieving target selectivity. By utilizing X-ray structural information for four promiscuous inhibitors, we propose a five-point pharmacophore for kinase frequent hitters, demonstrate its ability to discriminate between frequent hitters and selective ligands, and suggest a strategy for selective inhibitor design.

引用

页码：5616 / 5619

页数：4

共 20 条

[1] The properties of known drugs .1. Molecular frameworks
Bemis, GW
Murcko, MA
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) : 2887 - 2893
[2] Protein kinase a in complex with rho-kinase inhibitors Y-27632, fasudil, and H-1152P: Structural basis of selectivity
Breitenlechner, C
Gassel, M
Hidaka, H
Kinzel, V
Huber, R
Engh, RA
Bossemeyer, D
[J]. STRUCTURE, 2003, 11 (12) : 1595 - 1607
[3] Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug
Capdeville, R
Buchdunger, E
Zimmermann, J
Matter, A
[J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) : 493 - 502
[4] Issues and progress with protein kinase inhibitors for cancer treatment
Dancey, J
Sausville, EA
[J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (04) : 296 - 313
[5] Kinases, homology models, and high throughput docking
Diller, DJ
Li, RX
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (22) : 4638 - 4647
[6] METHODS FOR DRUG DISCOVERY - DEVELOPMENT OF POTENT, SELECTIVE, ORALLY EFFECTIVE CHOLECYSTOKININ ANTAGONISTS
EVANS, BE
RITTLE, KE
BOCK, MG
DIPARDO, RM
FREIDINGER, RM
WHITTER, WL
LUNDELL, GF
VEBER, DF
ANDERSON, PS
CHANG, RSL
LOTTI, VJ
CERINO, DJ
CHEN, TB
KLING, PJ
KUNKEL, KA
SPRINGER, JP
HIRSHFIELD, J
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (12) : 2235 - 2246
[7] CDK versus GSK-3 inhibition: a purple haze no longer?
Fischer, PM
[J]. CHEMISTRY & BIOLOGY, 2003, 10 (12): : 1144 - 1146
[8] An efficient proteomics method to identify the cellular targets of protein kinase inhibitors
Godl, K
Wissing, J
Kurtenbach, A
Habenberger, P
Blencke, S
Gutbrod, H
Salassidis, K
Stein-Gerlach, M
Missio, A
Cotten, M
Daub, H
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (26) : 15434 - 15439
[9] Privileged molecules for protein binding identified from NMR-based screening
Hajduk, PJ
Bures, M
Praestgaard, J
Fesik, SW
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (18) : 3443 - 3447
[10] Klabunde T, 2002, CHEMBIOCHEM, V3, P929, DOI 10.1002/1439-7633(20021004)3:10<928::AID-CBIC928>3.0.CO

← 1 2 →